Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) Revolutionary Process Creates Superior Cannabinoid Edibles
- Disruptive, patented technology is set to revolutionize the edible cannabis market
- Company has patent applications in 45 countries, including 18 applications in the U.S.
- Technology is patent-protected for CBD and all other non-psychoactive cannabinoids, with patents pending for THC, other psychoactive cannabinoids, NSAIDs, nicotine and other molecules
A common complaint among the consumers of cannabis edibles is an unpleasant taste that can often be detected, but that unpleasant taste and other inadequacies of cannabis edibles are being overcome thanks to the incredible innovations of Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP).
Lexaria is literally bringing new flavor to the marijuana industry with its disruptive process, which masks the unpleasant taste associated with cannabis. Lexaria’s lipophilic enhancement technology also changes the way cannabinoids enter the body; substantially speeds up the time frame in which tetrahydrocannabinol (THC) effects can be felt after consuming a cannabinoid edible; and increases bio-absorption by up to 10 times, making the absorption from cannabis edibles equal to the absorption from inhaled cannabis.
Because cannabinoids are absorbed poorly by the gastrointestinal tract, many cannabis users turn to other administration routes, like smoking, for greater effectiveness. Lexaria’s proprietary technology for better delivery of bioactive compounds solves the problem of poor absorption, increasing the bio-absorption of cannabis edibles by between five and tenfold. The effects of the THC from an edible product created using Lexaria’s patented process are also felt much more quickly—taking effect within 15-20 minutes as opposed to one to two hours.
The possibilities enabled by Lexaria’s technology are multifold and exciting. For instance, excessive amounts of sugar have previously had to be included in cannabis edibles to mask the unwanted taste, but because Lexaria’s technology eliminates that undesirable flavor, zero-sugar formats are now possible for cannabinoid edibles.
Lexaria’s process involves taking the healthy cocktail of molecules found in the company’s organically sourced hemp and infusing those molecules inside the molecules of other ingredients. Lexaria works with lipids, because the endocannabinoid system in the human body is lipid-based. The company has found its method to be a more efficient means of delivering hemp oil ingredients to the body, making a small amount of hemp seed oil inside a Lexaria product equal to a great deal of hemp oil delivered via a product that wasn’t created using the company’s revolutionary technology.
Lexaria’s pioneering technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids. Patents are further pending for THC and other psychoactive cannabinoids, along with nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. In the United States, 18 patent applications have been filed, and international and national patent filings have been made in 44 other countries.
For more information, visit the company’s website at www.LexariaEnergy.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Disruptive, patented technology is set to revolutionize the edible cannabis market
- Company has patent applications in 45 countries, including 18 applications in the U.S.
- Technology is patent-protected for CBD and all other non-psychoactive cannabinoids, with patents pending for THC, other psychoactive cannabinoids, NSAIDs, nicotine and other molecules
A common complaint among the consumers of cannabis edibles is an unpleasant taste that can often be detected, but that unpleasant taste and other inadequacies of cannabis edibles are being overcome thanks to the incredible innovations of Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP).
Lexaria is literally bringing new flavor to the marijuana industry with its disruptive process, which masks the unpleasant taste associated with cannabis. Lexaria’s lipophilic enhancement technology also changes the way cannabinoids enter the body; substantially speeds up the time frame in which tetrahydrocannabinol (THC) effects can be felt after consuming a cannabinoid edible; and increases bio-absorption by up to 10 times, making the absorption from cannabis edibles equal to the absorption from inhaled cannabis.
Because cannabinoids are absorbed poorly by the gastrointestinal tract, many cannabis users turn to other administration routes, like smoking, for greater effectiveness. Lexaria’s proprietary technology for better delivery of bioactive compounds solves the problem of poor absorption, increasing the bio-absorption of cannabis edibles by between five and tenfold. The effects of the THC from an edible product created using Lexaria’s patented process are also felt much more quickly—taking effect within 15-20 minutes as opposed to one to two hours.
The possibilities enabled by Lexaria’s technology are multifold and exciting. For instance, excessive amounts of sugar have previously had to be included in cannabis edibles to mask the unwanted taste, but because Lexaria’s technology eliminates that undesirable flavor, zero-sugar formats are now possible for cannabinoid edibles.
Lexaria’s process involves taking the healthy cocktail of molecules found in the company’s organically sourced hemp and infusing those molecules inside the molecules of other ingredients. Lexaria works with lipids, because the endocannabinoid system in the human body is lipid-based. The company has found its method to be a more efficient means of delivering hemp oil ingredients to the body, making a small amount of hemp seed oil inside a Lexaria product equal to a great deal of hemp oil delivered via a product that wasn’t created using the company’s revolutionary technology.
Lexaria’s pioneering technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids. Patents are further pending for THC and other psychoactive cannabinoids, along with nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. In the United States, 18 patent applications have been filed, and international and national patent filings have been made in 44 other countries.
For more information, visit the company’s website at www.LexariaEnergy.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
